Scarica l'app Stockscreener
4.87
0.41%
0.02
Dopo l'orario di chiusura:
4.87
Precedente Chiudi:
$4.85
Aprire:
$4.89
Volume 24 ore:
1.30M
Relative Volume:
2.04
Capitalizzazione di mercato:
$270.77M
Reddito:
$40.37M
Utile/perdita netta:
$-119.72M
Rapporto P/E:
-2.387
EPS:
-2.0402
Flusso di cassa netto:
$-135.06M
1 W Prestazione:
+23.92%
1M Prestazione:
+42.40%
6M Prestazione:
+16.51%
1 anno Prestazione:
+19.95%
Intervallo 1D:
$4.79
$5.025
Intervallo di 1 settimana:
$3.765
$5.478
Portata 52W:
$2.645
$5.55
Voyager Therapeutics Inc Stock (VYGR) Company Profile
Nome
Voyager Therapeutics Inc
Settore
Industria
Telefono
857-259-5340
Indirizzo
75 HAYDEN AVENUE, LEXINGTON, MA
Compare VYGR vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VYGR
Voyager Therapeutics Inc
|
4.87 | 269.66M | 40.37M | -119.72M | -135.06M | -2.0402 |
|
VRTX
Vertex Pharmaceuticals Inc
|
478.13 | 125.08B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
746.61 | 81.90B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
708.85 | 45.06B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
317.23 | 42.50B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
285.30 | 33.16B | 5.36B | 287.73M | 924.18M | 2.5229 |
Voyager Therapeutics Inc Stock (VYGR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-01-10 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-12-02 | Iniziato | Citigroup | Buy |
| 2024-11-29 | Ripresa | Wedbush | Outperform |
| 2024-10-16 | Iniziato | Leerink Partners | Outperform |
| 2024-03-26 | Iniziato | Guggenheim | Buy |
| 2024-03-19 | Iniziato | H.C. Wainwright | Buy |
| 2024-03-07 | Iniziato | Citigroup | Buy |
| 2024-01-02 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-05-10 | Iniziato | Truist | Buy |
| 2023-03-10 | Iniziato | Oppenheimer | Outperform |
| 2021-10-07 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2021-02-26 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2021-02-03 | Downgrade | BTIG Research | Buy → Neutral |
| 2021-02-03 | Downgrade | Wedbush | Outperform → Neutral |
| 2020-12-24 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2020-12-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2020-11-11 | Downgrade | Oppenheimer | Outperform → Perform |
| 2020-11-10 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2020-11-10 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2020-03-19 | Iniziato | The Benchmark Company | Buy |
| 2020-02-06 | Iniziato | Oppenheimer | Outperform |
| 2018-11-15 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2018-09-10 | Ripresa | BTIG Research | Buy |
| 2018-09-10 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2018-06-04 | Iniziato | H.C. Wainwright | Buy |
| 2018-03-12 | Downgrade | Evercore ISI | Outperform → In-line |
| 2018-03-12 | Downgrade | Wedbush | Outperform → Neutral |
| 2018-02-02 | Iniziato | Morgan Stanley | Overweight |
| 2017-11-28 | Ripresa | Piper Jaffray | Overweight |
| 2017-10-31 | Iniziato | Robert W. Baird | Outperform |
| 2017-10-27 | Iniziato | Canaccord Genuity | Buy |
| 2017-10-23 | Reiterato | Stifel | Buy |
| 2017-10-12 | Iniziato | Raymond James | Outperform |
| 2017-08-17 | Iniziato | Evercore ISI | Outperform |
| 2017-07-28 | Ripresa | Stifel | Buy |
Mostra tutto
Voyager Therapeutics Inc Borsa (VYGR) Ultime notizie
Voyager Therapeutics, Inc. (NASDAQ:VYGR) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Voyager Therapeutics Faces Rising Tariff and U.S.–China Geopolitical Risks as BIOSECURE Act Threatens Key Chinese CDMO Partnerships - TipRanks
Voyager Therapeutics (VYGR) Q4 Loss Of US$27 Million Reinforces Bearish Profitability Concerns - simplywall.st
Voyager Therapeutics, Inc. 2025 Annual Report: Key Risks, Forward-Looking Statements, and Business Overview - Minichart
Voyager Therapeutics Inc earnings beat by $0.05, revenue topped estimates - Investing.com UK
Voyager Therapeutics (VYGR) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance
Voyager Therapeutics Q4 2025 Financial Report: Revenue Surpasses EstimatesNews and StatisticsIndexBox - IndexBox - Market Intelligence Platform
Voyager (VYGR) Surpasses Q4 Revenue Expectations, Sets Strategic Vision for 2026 - GuruFocus
Voyager Therapeutics: Fourth Quarter Earnings Overview - Bitget
Gene therapy pioneer Voyager Therapeutics Inc (stock code: VYGR) announced that by the end of fiscal year 2025, the company held strong cash and cash equivalents totaling $202 million. - Bitget
Voyager Therapeutics (NASDAQ:VYGR) Announces Earnings Results, Beats Expectations By $0.08 EPS - MarketBeat
Voyager Therapeutics: Q4 Earnings Snapshot - 10TV
Voyager Therapeutics reports Q4 2025: $15.3M Q4 collaboration revenue, $119.7M full-year net loss - TradingView
Voyager Therapeutics 2025 10-K: Collaboration revenue $40.4M, Net loss $(119.7)M - TradingView
Voyager Reports Fourth Quarter and Full Year 2025 Financial and Operating Results - GlobeNewswire
Is Voyager Therapeutics Inc. stock trading at a premium valuation2026 Summary & Expert-Curated Trade Recommendations - Naître et grandir
Will Voyager Therapeutics Inc. stock gain from lower inflationEarnings Growth Report & Fast Entry Momentum Alerts - mfd.ru
Voyager Therapeutics Inc expected to post a loss of 51 cents a shareEarnings Preview - TradingView
Voyager Therapeutics (VYGR) to Release Quarterly Earnings on Tuesday - MarketBeat
Voyager Therapeutics Touts Tau, Gene Therapy and NeuroShuttle Roadmap, Sees Cash Runway Into 2028 - Defense World
Voyager Therapeutics at Oppenheimer Conference: Strategic Insights on Alzheimer’s By Investing.com - Investing.com Canada
Todd Alfred Carter Sells 4,174 Shares of Voyager Therapeutics (NASDAQ:VYGR) Stock - MarketBeat
Voyager Therapeutics (NASDAQ:VYGR) CFO Sells $17,598.36 in Stock - MarketBeat
Voyager Therapeutics (NASDAQ:VYGR) CEO Alfred Sandrock Sells 14,197 Shares - MarketBeat
Robin Swartz, Voyager Therapeutics COO, sells $24k in VYGR stock - Investing.com Canada
Alfred Sandrock, Voyager Therapeutics CEO, sells $53806 in stock By Investing.com - Investing.com Canada
Voyager Therapeutics CFO sells $17,598 in stock By Investing.com - Investing.com Canada
VYGR | Voyager Therapeutics, Inc. Common FinancialsIncome Statement - Quiver Quantitative
Voyager Therapeutics (VYGR) CFO executes 4,668-share tax sell-to-cover trade - Stock Titan
Voyager Therapeutics (VYGR) CSO auto-sells shares for tax bill - Stock Titan
Earnings Miss: How does Voyager Therapeutics Inc compare to its peersGlobal Markets & Accurate Buy Signal Notifications - baoquankhu1.vn
ARMISTICE CAPITAL, LLC Reduces Stake in Voyager Therapeutics Inc. - GuruFocus
4,174-Share Rule 144 Notice for Voyager Therapeutics (NASDAQ: VYGR) - Stock Titan
VYGR (NASDAQ: VYGR) Rule 144 notice: 6,458 shares tied to vesting - Stock Titan
14,197 shares vest; director sold 12,192 and 11,732 (VYGR) - Stock Titan
VYGR Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Voyager Therapeutics (NASDAQ:VYGR) Rating Lowered to "Sell" at Wall Street Zen - MarketBeat
[Form 4] Voyager Therapeutics, Inc. Insider Trading Activity - Stock Titan
Is Voyager Therapeutics Inc. stock a smart retirement pickEarnings Overview Report & Daily Market Momentum Tracking - mfd.ru
Tax-driven sale: Voyager (NASDAQ: VYGR) CSO sells 3,301 shares - Stock Titan
Voyager Therapeutics (VYGR) Form 144: 3,301-share proposed sale; insider sold 3,525 - Stock Titan
EcoR1 discloses 6.8% Voyager Therapeutics (VYGR) ownership stake - Stock Titan
Voyager Therapeutics, Inc. (NASDAQ:VYGR) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Published on: 2026-02-14 07:15:36 - mfd.ru
Voyager Therapeutics Announces Chief Medical Officer Resignation - The Globe and Mail
What analyst consensus says on Voyager Therapeutics Inc. stockDividend Hike & Target Return Focused Picks - mfd.ru
Is Voyager Therapeutics Inc. subject to activist investor interestWeekly Investment Summary & Daily Chart Pattern Signals - mfd.ru
Todd Alfred Carter Sells 3,525 Shares of Voyager Therapeutics (NASDAQ:VYGR) Stock - MarketBeat
Voyager Therapeutics (NASDAQ:VYGR) COO Sells $17,590.65 in Stock - MarketBeat
Earnings Miss: Can Voyager Therapeutics Inc reach all time highs this year2025 Growth vs Value & AI Powered Market Entry Ideas - baoquankhu1.vn
Alfred Sandrock Sells 12,192 Shares of Voyager Therapeutics (NASDAQ:VYGR) Stock - MarketBeat
Voyager Therapeutics Inc Azioni (VYGR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Voyager Therapeutics Inc Azioni (VYGR) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Sandrock Alfred | President and CEO |
Feb 24 '26 |
Sale |
3.79 |
14,197 |
53,807 |
484,060 |
| Jorgensen Nathan D. | Chief Financial Officer |
Feb 24 '26 |
Sale |
3.77 |
4,668 |
17,598 |
151,416 |
| Carter Todd Alfred | Chief Scientific Officer |
Feb 24 '26 |
Sale |
3.76 |
4,174 |
15,694 |
145,718 |
1.76%
0.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):